

# Katharina Mahal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10811809/publications.pdf>

Version: 2024-02-01

13  
papers

311  
citations

1040056

9  
h-index

1125743

13  
g-index

13  
all docs

13  
docs citations

13  
times ranked

587  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of chrysin, apigenin, genistein and their homoleptic copper(II) complexes on the growth and metastatic potential of cancer cells. <i>Journal of Inorganic Biochemistry</i> , 2013, 127, 107-115.	3.5	69
2	Ferrocene and (arene)ruthenium(II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action. <i>Journal of Inorganic Biochemistry</i> , 2014, 138, 64-72.	3.5	39
3	Improved anticancer and antiparasitic activity of new lawsone Mannich bases. <i>European Journal of Medicinal Chemistry</i> , 2017, 126, 421-431.	5.5	39
4	Effects of the Tumor Vasculature Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels. <i>ChemMedChem</i> , 2014, 9, 847-854.	3.2	32
5	Cancer Selective Metallocenedicarboxylates of the Fungal Cytotoxin Illudin M. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 6177-6182.	6.4	31
6	Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. <i>European Journal of Medicinal Chemistry</i> , 2016, 118, 9-20.	5.5	29
7	Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. <i>Investigational New Drugs</i> , 2015, 33, 541-554.	2.6	22
8	New ferrocene modified lawsone Mannich bases with anti-proliferative activity against tumor cells. <i>Journal of Saudi Chemical Society</i> , 2017, 21, 105-110.	5.2	22
9	Biological evaluation of 4,5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 691-700.	2.3	11
10	4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide – A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. <i>Experimental Cell Research</i> , 2015, 336, 263-275.	2.6	9
11	Role of JNK and NF- $\kappa$ B in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , 2015, 38, 463-478.	4.4	4
12	Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 85-90.	2.3	3
13	Activity of a Doxorubicin Menthol Conjugate Against Circulating Epithelial Tumor Cells of Cancer Patients. <i>Journal of Pharmaceutical Sciences and Pharmacology</i> , 2014, 1, 233-236.	0.2	1